Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMPNASDAQ:APVONASDAQ:CLRBNASDAQ:LEXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsAPVOAptevo Therapeutics$3.25-22.1%$8.23$2.81▼$485.37$3.15M5.77594,409 shs1.27 million shsCLRBCellectar Biosciences$0.30+2.1%$0.30$0.22▼$3.15$15.86M0.524.02 million shs2.24 million shsLEXXLexaria Bioscience$0.97+0.7%$1.12$0.92▼$4.38$16.86M0.84148,560 shs152,542 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%APVOAptevo Therapeutics0.00%-5.01%-24.29%-91.01%-99.97%CLRBCellectar Biosciences0.00%-29.38%+17.14%-25.22%-89.80%LEXXLexaria Bioscience0.00%-1.69%-12.73%-45.45%-64.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAPVOAptevo Therapeutics3.2337 of 5 stars3.55.00.00.02.90.01.3CLRBCellectar Biosciences3.058 of 5 stars3.25.00.00.03.20.01.3LEXXLexaria Bioscience2.0018 of 5 stars3.52.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis Pharmaceuticals 0.00N/AN/AN/AAPVOAptevo Therapeutics 3.00Buy$219,040.006,739,592.31% UpsideCLRBCellectar Biosciences 2.33Hold$12.504,097.45% UpsideLEXXLexaria Bioscience 3.00Buy$7.00623.81% UpsideCurrent Analyst Ratings BreakdownLatest CLRB, LEXX, APVO, and ADMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00APVOAptevo Therapeutics$3.11M0.79N/AN/A$65.21 per share0.05CLRBCellectar BiosciencesN/AN/AN/AN/A$0.30 per shareN/ALEXXLexaria Bioscience$460K36.92N/AN/A$0.48 per share2.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)CLRBCellectar Biosciences-$44.58M-$0.73N/AN/AN/AN/A-619.70%-158.04%8/11/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.59N/AN/AN/A-1,784.03%-111.84%-100.48%7/11/2025 (Estimated)Latest CLRB, LEXX, APVO, and ADMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/11/2025N/ALEXXLexaria Bioscience-$0.15N/AN/AN/A$0.17 millionN/A5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/13/2025Q1 2025CLRBCellectar Biosciences-$0.17-$0.13+$0.04-$0.14N/AN/A4/14/2025Q2 2025LEXXLexaria Bioscience-$0.16-$0.15+$0.01-$0.15$0.14 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19APVOAptevo TherapeuticsN/A0.670.67CLRBCellectar BiosciencesN/A2.472.47LEXXLexaria BioscienceN/A4.244.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%APVOAptevo Therapeutics8.06%CLRBCellectar Biosciences16.41%LEXXLexaria Bioscience13.06%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%APVOAptevo Therapeutics0.12%CLRBCellectar Biosciences5.04%LEXXLexaria Bioscience26.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableAPVOAptevo Therapeutics50760,000755,000Not OptionableCLRBCellectar Biosciences1054.36 million51.62 millionOptionableLEXXLexaria Bioscience717.56 million12.92 millionNot OptionableCLRB, LEXX, APVO, and ADMP HeadlinesRecent News About These CompaniesLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23 at 9:15 AM | thenewswire.comLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23 at 9:15 AM | accessnewswire.comLexaria Bioscience announces completion of GLP-1-H25-5 studyJune 12, 2025 | finance.yahoo.comLexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | thenewswire.comLexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | accessnewswire.comLexaria Bioscience Corp.: Lexaria Attending BIO International ConventionJune 5, 2025 | finanznachrichten.deLexaria Attending BIO International ConventionJune 5, 2025 | thenewswire.comLexaria Attending BIO International ConventionJune 5, 2025 | accessnewswire.comLexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 12, 2025 | accessnewswire.comLexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 12, 2025 | thenewswire.comLexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | thenewswire.comLexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | accessnewswire.comLexaria Bioscience prices 2M shares at $1.00 in registered direct offeringApril 26, 2025 | markets.businessinsider.comLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | accessnewswire.comLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | thenewswire.comLexaria provides GLP-1 update following industry developmentsApril 23, 2025 | markets.businessinsider.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s TechnologyApril 23, 2025 | finance.yahoo.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's TechnologyApril 23, 2025 | accessnewswire.comWe Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth CarefullyApril 5, 2025 | uk.finance.yahoo.comLexaria Updates its Ongoing Human Study GLP-1-H24-4April 3, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLRB, LEXX, APVO, and ADMP Company DescriptionsAdamis Pharmaceuticals NASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Aptevo Therapeutics NASDAQ:APVO$3.25 -0.92 (-22.06%) Closing price 04:00 PM EasternExtended Trading$3.24 -0.01 (-0.31%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Cellectar Biosciences NASDAQ:CLRB$0.30 +0.01 (+2.06%) Closing price 04:00 PM EasternExtended Trading$0.29 0.00 (-1.28%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Lexaria Bioscience NASDAQ:LEXX$0.97 +0.01 (+0.74%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.02 (+2.37%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
